Once upon a time, Ginkgo Bioworks (NYSE: DNA) was viewed by many as a rising star in the biotechnology world. However, since its initial public offering in September 2021, the stock has plunged 95%. So far in 2024, Ginkgo's shares have fallen more than 60%. Can Ginkgo Bioworks stage a major comeback? ...
motleyfoolusx:dna
Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (NYSE: DNA) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those plans would make it a smart stock to own as ...
motleyfoolusx:dna
It has been difficult to be a shareholder of Ginkgo Bioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is an amazing accomplishment, but sales have stagnated. If this business only needs a little more time for the ...
motleyfoolusx:dna
Ginkgo Bioworks (NYSE: DNA) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mark Massaro downgraded Ginkgo stock to sell, and lowered his price on this biotech penny stock to just ...
motleyfoolusx:dna
Ginkgo Bioworks (NYSE: DNA) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the problem is it may take more than a decade for those ...
motleyfoolusx:dna
As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (NYSE: DNA), Recursion Pharmaceuticals (NASDAQ: RXRX), and Schrödinger ...
motleyfoolusx:sdgrusx:rxrxusx:dna
As I checked over my Stocks and Shares ISA portfolio at the weekend, two shares stood out. Not in a good way, unfortunately. One FTSE 100 stock has plunged by 48% since I invested (twice!) last year, while the other is down 61%. I’m now left wondering whether I should cut my losses and invest elsewhere. ...
motleyfooluklse:ocdousx:dna
